SAB Biotherapeutics (SABS) Enterprise Value (2020 - 2025)
Historic Enterprise Value for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to -$110.9 million.
- SAB Biotherapeutics' Enterprise Value fell 26438.57% to -$110.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.9 million, marking a year-over-year decrease of 26438.57%. This contributed to the annual value of -$20.8 million for FY2024, which is 6329.83% up from last year.
- Latest data reveals that SAB Biotherapeutics reported Enterprise Value of -$110.9 million as of Q3 2025, which was down 26438.57% from -$5.7 million recorded in Q2 2025.
- Over the past 5 years, SAB Biotherapeutics' Enterprise Value peaked at -$2.4 million during Q3 2023, and registered a low of -$110.9 million during Q3 2025.
- Moreover, its 5-year median value for Enterprise Value was -$16.6 million (2022), whereas its average is -$25.5 million.
- In the last 5 years, SAB Biotherapeutics' Enterprise Value tumbled by 115457.53% in 2024 and then surged by 8469.29% in 2025.
- Quarter analysis of 5 years shows SAB Biotherapeutics' Enterprise Value stood at -$39.5 million in 2021, then skyrocketed by 61.95% to -$15.0 million in 2022, then tumbled by 275.93% to -$56.6 million in 2023, then surged by 63.3% to -$20.8 million in 2024, then plummeted by 434.09% to -$110.9 million in 2025.
- Its last three reported values are -$110.9 million in Q3 2025, -$5.7 million for Q2 2025, and -$12.9 million during Q1 2025.